2022-RA-585-ESGO Come back to the future: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification

Abstract

[1]  A. Talhouk,et al.  Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  C. Genestie,et al.  Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry , 2022, British Journal of Cancer.

[3]  J. Ledermann,et al.  Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program , 2022, International Journal of Gynecological Cancer.

[4]  G. Scambia,et al.  Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis , 2022, Cancer.

[5]  G. Scambia,et al.  The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. , 2022, Gynecologic oncology.

[6]  L. Insabato,et al.  Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis , 2022, Archives of Gynecology and Obstetrics.

[7]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[8]  D. Kenwright,et al.  Molecular Profiling of Endometrial Cancer: An Exploratory Study in Aotearoa, New Zealand , 2021, Cancers.

[9]  C. Moiola,et al.  Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. , 2021, Gynecologic oncology.

[10]  M. Mueller,et al.  Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer , 2021, medRxiv.

[11]  G. Scambia,et al.  Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study , 2021, Journal of gynecologic oncology.

[12]  D. Santini,et al.  ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification , 2021, Cancers.

[13]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[14]  S. Leung,et al.  The cut-off for estrogen and progesterone receptor in endometrial cancer revisited: an ENITEC collaboration study. , 2020, Human pathology.

[15]  Jingxian Wu,et al.  Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer , 2020, Cancer management and research.

[16]  H. Putter,et al.  PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer , 2020, International Journal of Gynecological Cancer.

[17]  H. Putter,et al.  Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Gilks,et al.  Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.

[19]  T. Noda,et al.  Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma. , 2019, The American journal of pathology.

[20]  M. Guida,et al.  TCGA molecular groups of endometrial cancer: Pooled data about prognosis. , 2019, Gynecologic oncology.

[21]  P. Goodfellow,et al.  Mismatch repair deficiency identifies patients with high‐intermediate–risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker , 2018, Cancer.

[22]  Hongwei Zhang,et al.  The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification , 2018, Journal of gynecologic oncology.

[23]  C. Gilks,et al.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups , 2018, The American journal of surgical pathology.

[24]  A. Talhouk,et al.  Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  C. Marchetti,et al.  Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer , 2018, International Journal of Gynecologic Cancer.

[26]  K. K. van de Vijver,et al.  Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study , 2018, International Journal of Gynecologic Cancer.

[27]  L. Pusztai,et al.  Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Samuel Leung,et al.  Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification , 2017, The journal of pathology. Clinical research.

[29]  Wei Chen,et al.  Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. , 2017, Gynecologic oncology.

[30]  A. Talhouk,et al.  Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.

[31]  Shamshad Ali,et al.  Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma , 2016, International Journal of Gynecologic Cancer.

[32]  D. Tritchler,et al.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[34]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[35]  P. Pollock,et al.  Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.

[36]  H. Tsuda,et al.  DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers , 2015, Journal of gynecologic oncology.

[37]  J. Marcickiewicz,et al.  Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. , 2013, European journal of cancer.

[38]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[39]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.